Literature DB >> 15651064

Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.

Anders Bjartell1, Annukka Paju, Wan-Ming Zhang, Virgil Gadaleanu, Jens Hansson, Göran Landberg, Ulf-Håkan Stenman.   

Abstract

BACKGROUND: Trypsinogens are pancreatic serine proteinases and expressed in several cancers as tumor-associated trypsinogens (TAT). Trypsin mediates activation of pro-uPA and pro-MMPs, thus promoting angiogenesis and tumor invasion. Recently, we described expression of TAT in the human male genital tract and now we studied TAT in relation to PSA in PCa.
METHODS: TAT expression was studied by immunohistochemistry, in situ hybridization, RT-PCR, DNA-sequencing and IFMA. LNCaP cells were used to study secretion of TAT and PSA after androgen stimulation.
RESULTS: Immunoreactive TAT was localized in all prostatic tumors (n = 109), lymph node (n = 16), and bone metastases (n = 17). Immunostaining intensity increased with higher Gleason's grade, whereas PSA immunostaining decreased significantly. PSA and TAT were not identically distributed in benign and malignant cells. Androgen stimulation of LNCaP cells decreased secretion of TAT and increased that of PSA. TAT mRNA was demonstrated in tissue sections and identified as TAT-1 and -2 by RT-PCR and DNA-sequencing.
CONCLUSIONS: Expression of TAT is better preserved than PSA in high-grade PCa. Expression of TAT and PSA is regulated by different mechanisms as demonstrated in tissue sections and in vitro. Locally produced TAT may act in a paracrine mode to promote angiogenesis and tumor invasion in PCa by both activating and degrading of other proteinases. Further studies on the role of TAT in invasive PCa and on the mechanisms involved in the regulation of TAT expression are warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15651064     DOI: 10.1002/pros.20236

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

Review 1.  Proteinase-activated receptors in the lower urinary tract.

Authors:  James D Moffatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-10       Impact factor: 3.000

2.  Therapeutic targeting of SPINK1-positive prostate cancer.

Authors:  Bushra Ateeq; Scott A Tomlins; Bharathi Laxman; Irfan A Asangani; Qi Cao; Xuhong Cao; Yong Li; Xiaoju Wang; Felix Y Feng; Kenneth J Pienta; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Sci Transl Med       Date:  2011-03-02       Impact factor: 17.956

3.  Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.

Authors:  Desta A Beyene; Tammey J Naab; Norma F Kanarek; Victor Apprey; Ashwini Esnakula; Farahan A Khan; Marc R Blackman; Collis A Brown; Tamaro S Hudson
Journal:  Prostate       Date:  2018-04-22       Impact factor: 4.104

4.  The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Authors:  Scott A Tomlins; Daniel R Rhodes; Jianjun Yu; Sooryanarayana Varambally; Rohit Mehra; Sven Perner; Francesca Demichelis; Beth E Helgeson; Bharathi Laxman; David S Morris; Qi Cao; Xuhong Cao; Ove Andrén; Katja Fall; Laura Johnson; John T Wei; Rajal B Shah; Hikmat Al-Ahmadie; James A Eastham; Scott E Eggener; Samson W Fine; Kristina Hotakainen; Ulf-Håkan Stenman; Alex Tsodikov; William L Gerald; Hans Lilja; Victor E Reuter; Phillip W Kantoff; Peter T Scardino; Mark A Rubin; Anders S Bjartell; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

5.  The levels of serine proteases in colon tissue interstitial fluid and serum serve as an indicator of colorectal cancer progression.

Authors:  Yingying Xie; Lechuang Chen; Xiaolei Lv; Guixue Hou; Yang Wang; Cuicui Jiang; Hongxia Zhu; Ningzhi Xu; Lin Wu; Xiaomin Lou; Siqi Liu
Journal:  Oncotarget       Date:  2016-05-31

6.  PRSS contributes to cetuximab resistance in colorectal cancer.

Authors:  Zhaoli Tan; Lihua Gao; Yan Wang; Huihui Yin; Yongyi Xi; Xiaojie Wu; Yong Shao; Weiyi Qiu; Peng Du; Wenlong Shen; Ling Fu; Ru Jia; Chuanhua Zhao; Yun Zhang; Zhihu Zhao; Zhiwei Sun; Hongxing Chen; Xianwen Hu; Jianming Xu; Youliang Wang
Journal:  Sci Adv       Date:  2020-01-01       Impact factor: 14.136

Review 7.  The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity.

Authors:  Kyung Chan Park; Mahendiran Dharmasivam; Des R Richardson
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923

8.  Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells.

Authors:  Mohammad K Ghalayini; Qihan Dong; Des R Richardson; Stephen J Assinder
Journal:  Biosci Rep       Date:  2013-06-11       Impact factor: 3.840

Review 9.  New intracellular and molecular aspects in pathophysiology of colorectal cancer.

Authors:  Payman Ziapour; Ramin Ataee; Mohammad Shadifar; Cathy Vaillancourt; Ali Ahmadi; Majid Jafari-Sabet; Amin Ataee
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2011
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.